Register a trial

The ANZCTR website is back online for trial registration and updates. We apologise for any inconvenience caused while the site was inactive.

Please note that the ANZCTR will be unattended from Friday 18th April until Tuesday 22nd April due to the Easter long weekend. Submissions and updates will not be processed during that time.



Reset your password and enable multi-factor authentication (MFA)


For ANZCTR account holders: to help ensure the cyber safety of your account, you’ll need to reset your password and set-up multi-factor authentication (MFA) as per the instructions below.


  1. Go to the Login page, click ‘reset password’ and follow the instructions.
  2. Check your email for the link to set a new password.
  3. Create a new password that meets requirements. New passwords must include at least one lowercase letter, one uppercase letter, one number and one special character (e.g. !#$%&@).
  4. Return to the Login page and enter your new password. A verification code will be sent to your email.
  5. Check your email for the code and enter it on the Login page. If the code is entered incorrectly, you can re-enter the correct one or request a new one.

Learn more about MFA and its importance on the Australian Signals Directorate website.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06760819




Registration number
NCT06760819
Ethics application status
Date submitted
18/12/2024
Date registered
25/03/2025

Titles & IDs
Public title
A Study to Learn More About How Well Treatment With BAY2927088 Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Scientific title
A Phase 2 Open-label Basket Study to Evaluate the Efficacy and Safety of Orally Administered Reversible Tyrosine Kinase Inhibitor BAY 2927088 in Participants With Metastatic or Unresectable Solid Tumors With HER2-activating Mutations
Secondary ID [1] 0 0
2024-517419-62-00
Secondary ID [2] 0 0
22752
Universal Trial Number (UTN)
Trial acronym
panSOHO
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Advanced Solid Tumors 0 0
HER2 Mutation 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional(has expanded access)
Description of intervention(s) / exposure
Treatment: Drugs - BAY2927088

Experimental: BAY2927088 - Adult participants with metastatic or unresectable solid tumors with HER-2 activating mutations including: colorectal, biliary tract, bladder, cervical, endometrial, and other solid tumor types. Participants will receive BAY2927088 20 mg BID until disease progression per RECICST 1.1, unacceptable toxicity, or until any other withdrawal criteria.

RECIST 1.1 = Response Evaluation Criteria in Solid Tumors, version 1.1; BID: twice a day


Treatment: Drugs: BAY2927088
tablet, oral
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Objective Response Rate (ORR) per RECIST 1.1 as assessed by BICR
Timepoint [1] 0 0
From start of study intervention until the first documented progression, or death from any cause, or end of study (up to approximately 3 years), whichever comes first
Secondary outcome [1] 0 0
Duration of response (DOR) per RECIST 1.1 as assessed by BICR
Timepoint [1] 0 0
From start of study intervention until the first documented progression, or death from any cause, or end of study (up to approximately 3 years), whichever comes first
Secondary outcome [2] 0 0
Time to response (TTR) per RECIST 1.1 as assessed by BICR
Timepoint [2] 0 0
From first participant enrolled until end of treatment or end of imaging active follow-up (up to approximately 3 years)
Secondary outcome [3] 0 0
ORR per RECIST 1.1 as assessed by the investigator
Timepoint [3] 0 0
From start of study intervention until the first documented progression, or death from any cause, or end of study (up to approximately 3 years), whichever comes first
Secondary outcome [4] 0 0
Disease control rate (DCR) per RECIST 1.1 as assessed by BICR
Timepoint [4] 0 0
From start of study intervention until the first documented progression, or death from any cause, or end of study (up to approximately 3 years), whichever comes first
Secondary outcome [5] 0 0
DCR =12 weeks per RECIST 1.1 as assessed by BICR
Timepoint [5] 0 0
From start of study intervention until the first documented progression, or death from any cause, or end of study (up to approximately 3 years), whichever comes first
Secondary outcome [6] 0 0
Progression-free survival (PFS) per RECIST 1.1 as assessed by BICR
Timepoint [6] 0 0
From start of study intervention until the first documented progression, or death from any cause, or end of study (up to approximately 3 years), whichever comes first
Secondary outcome [7] 0 0
Disease control rate (DCR) per RECIST 1.1 as assessed by the investigator
Timepoint [7] 0 0
From start of study intervention until the first documented progression, or death from any cause, or end of study (up to approximately 3 years), whichever comes first
Secondary outcome [8] 0 0
DCR =12 weeks per RECIST 1.1 as assessed by the investigator
Timepoint [8] 0 0
From start of study intervention until the first documented progression, or death from any cause, or end of study (up to approximately 3 years), whichever comes first
Secondary outcome [9] 0 0
Progression-free survival (PFS) per RECIST 1.1 as assessed by the investigator
Timepoint [9] 0 0
From start of study intervention until the first documented progression, or death from any cause, or end of study (up to approximately 3 years), whichever comes first
Secondary outcome [10] 0 0
DOR per RECIST 1.1 as assessed by the investigator
Timepoint [10] 0 0
From start of study intervention until the first documented progression, or death from any cause, or end of study (up to approximately 3 years), whichever comes first
Secondary outcome [11] 0 0
TTR per RECIST 1.1 as assessed by the investigator
Timepoint [11] 0 0
From first participant enrolled until end of treatment or end of imaging active follow-up (up to approximately 3 years)
Secondary outcome [12] 0 0
Overall survival (OS)
Timepoint [12] 0 0
From start of study intervention until death from any cause, or end of study (up to approximately 3 years), whichever comes first
Secondary outcome [13] 0 0
Number of participants with treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs) per CTCAE v 5.0, categorized by severity, including number of participants who discontinue study treatment due to an AE
Timepoint [13] 0 0
From first participant enrolled until up to 30 days after the last administration of study treatment
Secondary outcome [14] 0 0
Time to deterioration in EORTC QLQ-C30 physical functioning domain score
Timepoint [14] 0 0
Baseline and up until end of treatment or end of imaging active follow-up (up to approximately 3 years)
Secondary outcome [15] 0 0
Change from baseline in EORTC QLQ-C30 physical functioning domain score
Timepoint [15] 0 0
Baseline and up until end of treatment or end of imaging active follow-up (up to approximately 3 years)
Secondary outcome [16] 0 0
Change from baseline in EORTC QLQ-C30 global health status/quality of life (QoL)
Timepoint [16] 0 0
Baseline and up until end of treatment or end of imaging active follow-up (up to approximately 3 years)

Eligibility
Key inclusion criteria
* Documented histologically or cytologically confirmed locally advanced, unresectable or metastatic solid tumor cancer (colorectal carcinoma; biliary tract cancer; bladder and urothelial tract cancer; cervical cancer; endometrial cancer; other solid tumor cancer, excluding NSCLC)
* Participant must be =18 years of age or over the legal age of consent
* Patients who have received prior standard therapy appropriate for their tumor type and stage of disease, or who have no satisfactory alternative treatments
* Documented activating HER2 mutation
* At least one measurable lesion that would qualify as a target lesion by RECIST 1.1 criteria
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Primary diagnosis of non-small cell lung cancer (NSCLC)
* Prior treatment with a HER2 tyrosine kinase inhibitor (TKI)
* Active brain metastases
* Uncontrolled, severe, intercurrent illness

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
13/02/2025
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
25/10/2027
Actual
Sample size
Target
111
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD
Recruitment hospital [1] 0 0
Blacktown Cancer & Haematology Centre - Blacktown
Recruitment hospital [2] 0 0
Macquarie University Hospital - Sydney
Recruitment hospital [3] 0 0
ICON Cancer Centre - Southport - Southport
Recruitment postcode(s) [1] 0 0
2148 - Blacktown
Recruitment postcode(s) [2] 0 0
2109 - Sydney
Recruitment postcode(s) [3] 0 0
4215 - Southport
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Massachusetts
Country [5] 0 0
United States of America
State/province [5] 0 0
Michigan
Country [6] 0 0
United States of America
State/province [6] 0 0
Ohio
Country [7] 0 0
United States of America
State/province [7] 0 0
Tennessee
Country [8] 0 0
United States of America
State/province [8] 0 0
Texas
Country [9] 0 0
United States of America
State/province [9] 0 0
Washington
Country [10] 0 0
United States of America
State/province [10] 0 0
Wisconsin
Country [11] 0 0
Canada
State/province [11] 0 0
Nova Scotia
Country [12] 0 0
Canada
State/province [12] 0 0
Ontario
Country [13] 0 0
Canada
State/province [13] 0 0
Quebec
Country [14] 0 0
China
State/province [14] 0 0
Beijing
Country [15] 0 0
China
State/province [15] 0 0
Hunan
Country [16] 0 0
China
State/province [16] 0 0
Shanghai
Country [17] 0 0
China
State/province [17] 0 0
Zhejiang
Country [18] 0 0
Denmark
State/province [18] 0 0
Aarhus N
Country [19] 0 0
Denmark
State/province [19] 0 0
Copenhagen OE
Country [20] 0 0
Denmark
State/province [20] 0 0
Odense C
Country [21] 0 0
France
State/province [21] 0 0
Bordeaux
Country [22] 0 0
France
State/province [22] 0 0
Brest
Country [23] 0 0
France
State/province [23] 0 0
Lille
Country [24] 0 0
France
State/province [24] 0 0
Pierre-Benite
Country [25] 0 0
Italy
State/province [25] 0 0
Milano
Country [26] 0 0
Italy
State/province [26] 0 0
Reggio Emilia
Country [27] 0 0
Italy
State/province [27] 0 0
Roma
Country [28] 0 0
Japan
State/province [28] 0 0
Aichi
Country [29] 0 0
Japan
State/province [29] 0 0
Chiba
Country [30] 0 0
Japan
State/province [30] 0 0
Hokkaido
Country [31] 0 0
Japan
State/province [31] 0 0
Osaka
Country [32] 0 0
Japan
State/province [32] 0 0
Tokyo
Country [33] 0 0
Korea, Republic of
State/province [33] 0 0
Seoul Teugbyeolsi
Country [34] 0 0
Korea, Republic of
State/province [34] 0 0
Seoul
Country [35] 0 0
Spain
State/province [35] 0 0
Barcelona
Country [36] 0 0
Spain
State/province [36] 0 0
Navarra
Country [37] 0 0
Spain
State/province [37] 0 0
Madrid
Country [38] 0 0
Switzerland
State/province [38] 0 0
Bern
Country [39] 0 0
Switzerland
State/province [39] 0 0
Genève
Country [40] 0 0
Switzerland
State/province [40] 0 0
Zürich

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Bayer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Bayer Clinical Trials Contact
Address 0 0
Country 0 0
Phone 0 0
(+)1-888-84 22937
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries

Data sharing statement


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT06760819